This protease inhibitor shows two different activities, it inhibits both the capsaicin receptor TRPV1 and serine proteases. It partially blocks the capsaicin- and acid-induced response of TRPV1, a receptor of the pain pathway. It also weakly inhibits trypsin and chymotrypsin activity (Ki=0.5 uM and Ki=7 uM, respectively). In addition, it may also alter tachykinin levels by suppressing endogenous proteases. In vivo, it shows antinociceptive and analgesic activities. It significantly prolongs paw withdrawal latency and blocks heat-induced and chemical-induced acute pain. In addition, it also shows anti-inflammatory and analgesic effects in models of osteoarthritis and rheumatoid arthritis. In vivo, unlike other TRPV1 antagonists whose activity is associated with hyperthermia, this protein has the remarkable feature of dropping core body temperature